Mechanism of Action

Delgocitinib functions as a pan-Janus kinase (JAK) inhibitor, targeting all four members of the JAK family: JAK1, JAK2, JAK3, and TYK2. These kinases are intracellular signaling enzymes that associate with cytokine receptors and are essential for downstream STAT (Signal Transducer and Activator of Transcription) phosphorylation and nuclear translocation.

By blocking JAK catalytic activity, Delgocitinib interrupts cytokine-driven gene transcription involved in immune activation, proliferation, and inflammatory mediator release. This broad-spectrum JAK inhibition makes it particularly useful for research into conditions where multiple cytokine axes — including IL-4, IL-13, IL-31, IFN-γ, and others — are simultaneously dysregulated, as observed in atopic dermatitis, psoriasis, and other inflammatory skin disease models.

Researchers should note that pan-JAK inhibition produces a wider pharmacological profile compared with selective JAK1 or JAK3 inhibitors, which may introduce additional off-target considerations when interpreting pathway-specific data.

Handling, Solubility & Storage Guidelines

Reconstitution: Delgocitinib is commonly dissolved in dimethyl sulfoxide (DMSO) to prepare a concentrated stock solution. It is recommended to prepare aliquots to avoid repeated freeze-thaw cycles, which may compromise compound integrity. The final DMSO concentration in cell-based assays should generally not exceed 0.1% (v/v) to minimise cytotoxic artefacts; always include a vehicle control at an equivalent DMSO concentration.

Aqueous solubility: Like most kinase inhibitors, Delgocitinib has limited aqueous solubility. For assays requiring aqueous media, dilute the DMSO stock stepwise into the desired buffer or culture medium immediately before use. Verify absence of precipitation visually and, where feasible, by dynamic light scattering.

Storage: Store lyophilised or solid material at −20 °C in a desiccated environment, protected from light. Refer to the Certificate of Analysis (CoA) supplied with lot D656664 for lot-specific stability and expiry data. Prepared DMSO stock solutions may be stored at −20 °C for short-term use; for longer storage, −80 °C is advisable.

Safety: Handle under standard laboratory precautions for research-grade small molecules. Consult the Safety Data Sheet (SDS) before use. Delgocitinib is for research use only and is not intended for therapeutic, diagnostic, or human/veterinary use.

In Vitro Experimental Protocols

JAK-STAT phosphorylation inhibition assay:

1. Seed the appropriate cell line (e.g., keratinocytes, PBMCs, or relevant immune cell line) at the desired density; allow overnight adherence or equilibration.
2. Pre-treat cells with Delgocitinib at a range of concentrations (suggested starting range: 0.01–10 µM) for 30–60 minutes prior to cytokine stimulation.
3. Stimulate with the cytokine of interest (e.g., IL-4, IL-13, IFN-γ, or IL-6) at an empirically determined concentration for 15–30 minutes.
4. Lyse cells in ice-cold lysis buffer supplemented with phosphatase inhibitors. Quantify total protein by BCA or Bradford assay.
5. Assess phosphorylation status of STAT proteins (e.g., pSTAT3, pSTAT6) by Western blot or ELISA. Normalise to total STAT and housekeeping protein (e.g., β-actin or GAPDH).
6. Calculate percentage inhibition relative to vehicle-stimulated and unstimulated controls. Determine IC₅₀ using a four-parameter logistic curve fit.

Cell viability control: Run a parallel MTT or CellTiter-Glo assay to confirm compound concentrations used do not cause significant cytotoxicity.

Important note: Specific optimal concentrations, incubation times, and cytokine doses must be empirically determined for each cell type and assay system. The values above are indicative starting points only.

Quality Control & Lot-Specific Verification

Each lot of Delgocitinib (D656664) is accompanied by a Certificate of Analysis (CoA) confirming identity, purity, and appearance. Researchers are strongly advised to:

• Verify purity: Confirm ≥98% purity (or as stated on CoA) by HPLC prior to initiating critical experiments. Lower purity lots may confound biological results.
• Confirm identity: Cross-check molecular weight and structure against published data (MW: review CoA; CAS number: verify with Aladdin product page for D656664).
• Benchmark activity: Include a known positive-control inhibitor or use a reference cytokine stimulation assay to validate the activity of each new lot before committing to large-scale experiments.
• Document lot numbers: Record lot and batch numbers in all laboratory notebooks and publications to ensure reproducibility and traceability.

If any discrepancy is found between expected and observed activity, contact Aladdin Scientific technical support with your lot number and experimental details for assistance.